A Study in Patients With Trichotillomania

NCT ID: NCT03797521

Last Updated: 2021-10-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 128 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-12-19
• Study Completion Date: 2019-12-16

Brief Summary

The purpose of this study is to explore the safety, tolerability and activity of SXC-2023 when dosed for 6 weeks versus placebo in adult patients with moderate to severe Trichotillomania.

Detailed Description

This is a Phase 2, multicenter, double-blind, placebo-controlled, parallel-group study consisting of a screening period of up to 40 days, a 6 week randomized double-blind treatment period, followed by an up to 2 week safety follow-up period after the last dose of study medication.

Patients will be randomized to one of four treatment groups. Patients will participate for a total of up to 10 weeks, including screening, the 6-week treatment period and follow-up.

Conditions

Trichotillomania

Keywords

Promentis Pharmaceuticals; TTM; SXC-2023

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

SXC-2023 50mg QD

SXC-2023 50mg dosed once daily for 6 weeks

Group Type: EXPERIMENTAL

SXC-2023

Intervention Type: DRUG

SXC-2023 oral capsules

SXC-2023 200mg QD

SXC-2023 200mg dosed once daily for 6 weeks

Group Type: EXPERIMENTAL

SXC-2023

Intervention Type: DRUG

SXC-2023 oral capsules

SXC-2023 800mg QD

SXC-2023 800mg dosed once daily for 6 weeks

Group Type: EXPERIMENTAL

SXC-2023

Intervention Type: DRUG

SXC-2023 oral capsules

Matching Placebo QD

Matching Placebo dosed once daily for 6 weeks

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Matching Placebo oral capsules

Interventions

SXC-2023

SXC-2023 oral capsules

Intervention Type: DRUG

Placebo

Matching Placebo oral capsules

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Adult, female or male, 18-45 years of age, inclusive at screening.

2. Provided signed written informed consent with willingness and ability to comply with all aspects of the protocol.

3. Diagnosis of current TTM based on Diagnostic and Statistical Manual of Mental Disorders, fifth edition (DSM-5) criteria and confirmed using the clinician-administered MINI-TTM. In addition, subjects should:

1. Have a history of TTM for at least one year

2. Have a history of daily hair pulling for at least 6 months prior to the first dose

4. Except for SSRIs or SNRIs, has not used any psychoactive medications including, but not limited to, other antidepressants, anxiolytics, mood stabilizers, anti-psychotics, benzodiazepines, stimulants, sulfasalazine, and St. John's Wort 30 days prior to first dose. Subjects will be allowed to maintain background therapy with SSRIs or SNRIs if on stable regimen for a minimum of 90 days prior to first dose and there are no anticipated changes to the SSRI/SNRI during course of trial.

5. Has not used N-acetylcysteine for at least 90 days prior to the first dose.

6. Has not used gemfibrozil or repaglinide for 1 week prior to the first screening visit.

7. Medically healthy with no clinically significant findings in medical history, physical examination, laboratory profiles, vital signs, or ECGs, as deemed by the Principal Investigator (PI) or designee.

8. For a female of childbearing potential: either be sexually inactive (abstinent as a life style) for 28 days prior to the first dosing and throughout the study or be using one of the following acceptable birth control options:

• Oral contraception for at least 3 months prior to the first dosing along with either a physical (e.g., condom, diaphragm) or a chemical (e.g., spermicide) barrier method from the time of screening and throughout the study
• IUD (either hormone-releasing or non-hormone releasing) for at least minimum duration per current labeling along with either a physical (e.g., condom, diaphragm) or a chemical (e.g., spermicide) barrier method from the time of screening and throughout the study
• Depo contraception for at least minimum duration per current labeling prior to the first dosing along with either a physical (e.g., condom, diaphragm) or a chemical (e.g., spermicide) barrier method from the time of screening and throughout the study
• Double physical barrier method (e.g., condom and diaphragm) from 14 days prior to the first dose and throughout the study
• Physical plus chemical barrier method (e.g., condom with spermicide) from 14 days prior to the first dose and throughout the study.

In addition, female subjects of childbearing potential will be advised to remain sexually inactive or to keep the same birth control method for at least 30 days following the last dose.

9. Female of non childbearing potential: must have undergone one of the following sterilization procedures, at least 6 months prior to the first dose:

• hysteroscopic sterilization;
• bilateral tubal ligation or bilateral salpingectomy;
• hysterectomy;
• bilateral oophorectomy; Or be postmenopausal with amenorrhea for at least 1 year prior to the first dose with serum follicle stimulating hormone levels consistent with postmenopausal status or have medically documented history of biological or congenital sterility.

10. A non vasectomized, male subject must agree to use a condom with spermicide or abstain from sexual intercourse during the study until 30 days beyond the last dose of study drug/placebo.

11. If male, must agree not to donate sperm from the first dose until 30 days after the last dose administration.

12. Must be able to fluently read and write in English.

13. Understands the study procedures in the informed consent form (ICF) and is willing and able to comply with the protocol.

Exclusion Criteria

1. Females who are pregnant or breastfeeding or intend to become pregnant during the study period or within 30 days of the final dose of study drug.

2. Subjects engaged in cognitive behavioral therapy (CBT) for TTM or other body-focused repetitive behavior or any obsessive-compulsive related or impulse control disorder any time within 60 days prior to first dose. For other psychotherapies, subject must have been engaged in that psychotherapy for a minimum of 60 days at the time of first dose and must be willing to maintain the same frequency and type of therapy for the duration of the study period.

3. Subjects engaged in any other behavioral interventions (e.g., wearable devices, behavioral self-help strategies) within 60 days prior to first dose.

4. Mentally or legally incompetent.

5. Suffered a concussion in the past 6 months prior to screening. Any history of traumatic brain injury with loss of consciousness in the year prior to first screening visit.

6. Any lifetime history of any psychotic disorder, including schizophrenia or any bipolar or bipolar-related disorder as determined by clinical history or confirmed at screening with the MINI, version 7.0.2.

7. Current major depressive episode confirmed at screening with the MINI, version 7.0.2.

8. Per PI judgment, the presence of any emotional problems or psychiatric disorders that may obscure evaluation of primary TTM or pose a risk to subject safety or stability during the study period. Other emotional problems or diagnoses may include, but are not limited to, other body-focused repetitive behaviors, post-traumatic stress disorder, obsessive-compulsive disorder, panic disorder, compulsive gambling, borderline personality disorder, or antisocial personality disorder.

9. History of any injury, illness, or condition that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the subject by their participation in the study.

10. Laboratory evidence of renal impairment (e.g. a creatine clearance of < 80)

11. Presence of any substance use disorder or, in the opinion of the PI or designee, problematic substance use (excluding nicotine or caffeine) within the 2 years prior to screening.

12. History of seizure disorder with the exception of subjects who have been off anti-seizure medication and have not had a seizure in the past 5 years.

13. Subjects with any of the following:

1. Any psychiatric hospitalizations in the past year,

2. Imminent risk of suicide based on PI's or designee's clinical judgment or psychiatric examination,

3. Active suicidal ideation in the past 6 months as evidenced by positive endorsement to Item 4 or 5 on the C-SSRS, OR

4. Any history of suicidal behavior in the past year as evidenced by positive endorsement to any of the suicidal behavior items on the C-SSRS.

14. Has previously participated in any Promentis Phase 1 study.

15. Participation in another interventional clinical study (including CBT or other behavioral intervention) within 30 days prior to the first screening visit. The 30 day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to the date of initiation of screening in the current study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Promentis Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Dean Brostowin

Role: STUDY_DIRECTOR

Promentis Pharmaceuticals

Locations

CNRI- Los Angeles

Pico Rivera, California, United States

Artemis Institute for Clinical Research

Riverside, California, United States

Behavioral Clinical Research

North Miami, Florida, United States

iResearch Atlanta

Decatur, Georgia, United States

Univ of Chicago

Chicago, Illinois, United States

Lake Charles Clinical Trials

Lake Charles, Louisiana, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Integrative Clinical Trials, LLC

Brooklyn, New York, United States

Finger Lakes Clinical Research

Rochester, New York, United States

Insight Clinical Trials, LLC

Shaker Heights, Ohio, United States

IPS Research Company

Oklahoma City, Oklahoma, United States

Carolina Clinical Trials, Inc

Charleston, South Carolina, United States

Northwest Clinical Research Center

Bellevue, Washington, United States

Countries

United States

References

Hoffman J, Williams T, Rothbart R, Ipser JC, Fineberg N, Chamberlain SR, Stein DJ. Pharmacotherapy for trichotillomania. Cochrane Database Syst Rev. 2021 Sep 28;9(9):CD007662. doi: 10.1002/14651858.CD007662.pub3.

Reference Type: DERIVED

PMID: 34582562 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

PRO-201

Identifier Type: -

Identifier Source: org_study_id